北京市中伦律师事务所 关于华润双鹤药业股份有限公司 2021年限制性股票激励计划 部分限制性股票回购注销实施的 法律意见书 法律意见书 ZHONG LUN 中 倫 律 師 事 務 所 法律意见书 目 录 | 一、本次回购注销的批准和授权 . | | --- | | 二、本次回购注销的方案 … | | 三、本次回购注销的实施情况 | | 四、结论 … | 2 法律意见书 二〇二五年七月 1 关于华润双鹤药业股份有限公司 致：华润双鹤药业股份有限公司 根据华润双鹤药业股份有限公司（以下简称"华润双鹤"、"公司"）与北京市 中伦律师事务所（以下简称"本所"）签订的《专项法律服务合同》的约定，本所作 为公司2021年限制性股票激励计划（以下简称"激励计划"或"本次激励计划"）相 关事宜的专项法律顾问，就本次股权激励计划部分限制性股票回购注销（以下简称 "本次回购注销"）实施涉及的相关事项出具本法律意见书。 为出具本法律意见书，本所律师审阅了《华润双鹤药业股份有限公司2021年限制 性股票激励计划（2022年12月修订稿）》（以下简称"《激励计划（2022年12月修订 稿）》"）、《华润双鹤药业股份有限公司2021年限 ...

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－061 华润双鹤药业股份有限公司 关于全资子公司华润双鹤利民药业(济南)有限公司 通过GMP符合性检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"公司")全资子公司 华润双鹤利民药业(济南)有限公司(以下简称"双鹤利民")收到山东 省药品监督管理局颁发的《药品 GMP 符合性检查告知书》(编号： GMP2025164)，现将相关情况公告如下： 一、GMP 检查相关信息 被检查单位名称：华润双鹤利民药业(济南)有限公司 检查地址：山东省济南市章丘区明水街道利民路 1 号 检查范围：片剂、硬胶囊剂 生产车间和生产线：固体制剂六车间(片剂、硬胶囊剂生产线) 检查时间：2025 年 4 月 22 日—4 月 25 日 结论：经药品 GMP 符合性检查，符合《药品生产质量管理规范》 (2010 年版)的要求 本次检查为新建固体制剂六车间(片剂、硬胶囊剂生产线)药品 GMP 符合性检查，该车间新建的投入为人民币 2. ...

证券代码：600062 证券简称：华润双鹤 公告编号：临 2025－061 华润双鹤药业股份有限公司 生产车间和生产线：固体制剂六车间(片剂、硬胶囊剂生产线) 检查时间：2025 年 4 月 22 日—4 月 25 日 结论：经药品 GMP 符合性检查，符合《药品生产质量管理规范》 (2010 年版)的要求 本次检查为新建固体制剂六车间(片剂、硬胶囊剂生产线)药品 GMP 符合性检查，该车间新建的投入为人民币 2.60 亿元(未经审计)。 关于全资子公司华润双鹤利民药业(济南)有限公司 通过GMP符合性检查的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承 担法律责任。 近日，华润双鹤药业股份有限公司(以下简称"公司")全资子公司 华润双鹤利民药业(济南)有限公司(以下简称"双鹤利民")收到山东 省药品监督管理局颁发的《药品 GMP 符合性检查告知书》(编号： GMP2025164)，现将相关情况公告如下： 一、GMP 检查相关信息 被检查单位名称：华润双鹤利民药业(济南)有限公司 检查地址：山东省济南市章丘区明水街道利民路 1 号 ...

华润双鹤（600062）公告，全资子公司华润双鹤利民药业(济南)有限公司通过山东省药品监督管理局的 药品GMP符合性检查。该检查覆盖片剂和硬胶囊剂生产车间，涉及固体制剂六车间的片剂和硬胶囊剂 生产线。新建固体制剂六车间的投入为2.6亿元。公司硝苯地平控释片2024年销售收入为1.47亿元，盐酸 左氧氟沙星胶囊为2331.37万元。 ...

Core Viewpoint - The establishment of a 1 billion yuan investment fund by companies under China Resources, in collaboration with Shanghai Fosun Pharmaceutical and Chengdu state-owned enterprises, aims to focus on the pharmaceutical and health sectors, particularly in innovative drug development and strategic emerging industries [2][4]. Group 1: Fund Structure and Partners - The fund, named China Resources Pharmaceutical (Chengdu) Innovation Investment Fund, has a total capital of 100 million yuan, with various partners contributing different amounts [3]. - The general partner (GP) is China Resources Pharmaceutical (Chengdu) Enterprise Management Partnership (Limited Partnership), while limited partners (LPs) include several pharmaceutical companies and investment funds [2][3]. - The fund's lifespan is set for 7 years, with a 3-year investment period and a 4-year exit period, extendable by 1 year upon partner approval [3]. Group 2: Investment Focus - The fund will concentrate on the pharmaceutical health sector and strategic emerging industries, targeting areas such as chemical innovative drugs, biological drugs (including vaccines), high-end medical devices, and traditional Chinese medicine [4]. - The involvement of the Chengdu Bio-City Jingchuang Equity Investment Fund indicates a strong potential for project implementation within the Chengdu Tianfu International Bio-City [4]. Group 3: Historical Context - An earlier fund, the China Resources Pharmaceutical (Shantou) Industry Investment Fund, was established 8 years ago but did not perform as expected, failing to reach its initial target of 2.5 billion yuan [4][6]. - The Shantou fund entered a liquidation phase in December 2024, having not achieved the anticipated scale, which affected the contributions of its partners [5][6].

Core Viewpoint - China Resources Double Crane plans to invest in a new fund aimed at optimizing its strategic layout and enhancing innovation transformation while securing investment returns [1][2] Group 1: Fund Establishment - The company will collaborate with ten limited partners to establish the China Resources Medicine (Chengdu) Innovation Investment Fund with a target fundraising scale of 1 billion yuan [1] - China Resources Double Crane will contribute 40 million yuan, representing 4% of the total fund [1][2] - The fund will be managed by Shenzhen China Resources Capital Equity Investment Co., Ltd [1] Group 2: Strategic Intent - The investment aims to improve the company's ability to acquire and allocate quality resources, supporting long-term sustainable development and profitability [1] - The transaction is classified as a related party transaction due to the common control by China Resources [1][2] Group 3: Historical Context - The company previously established a similar fund in October 2017 with a total scale of 2.5 billion yuan, contributing 50 million yuan as a limited partner [2] - The first fund successfully identified and invested in projects that provided synergistic value, such as the acquisition of Tiandong Pharmaceutical, which laid a foundation for a biopharmaceutical platform [3]

重要内容提示： 交易简要内容：华润双鹤药业股份有限公司(以下简称"公司") 拟参与设立华润医药(成都)创新投资基金合伙企业(有限合伙)(暂定名， 以工商核准名为准，以下简称"本基金"或"该基金")。该基金目标募集 规模为 10 亿元人民币，公司拟以自有资金出资 4,000 万元人民币， 占基金总出资额的 4.00%。 本次交易构成关联交易，不构成重大资产重组。 本次交易已经公司内部有权机构审议批准，无需提交董事会和 股东会审议。 过去 12 个月内，除日常关联交易外，公司与中国华润有限公 司及其控制的主体无其他交易。 截至本公告披露日，该基金尚在筹备设立过程中，合伙协议尚 未签署，基金能否成功设立、募集规模及投资进度均存在不确定性。 基金具有投资周期长、流动性较低的特点，在投资运作过程中将受到 宏观经济、行业周期、政策法规等多种因素影响，可能面临投资收益 不达预期甚至本金损失的风险。 证券代码：600062 证券简称：华润双鹤 公告编号：临 2025-060 华润双鹤药业股份有限公司 关于参与设立华润医药产业投资基金二期 暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记 载、误导性陈述或 ...

Group 1 - The core viewpoint of the news is that the Artemisinin concept sector has seen a significant increase, with a rise of 2.65%, ranking third among concept sectors in terms of growth [1] - Within the Artemisinin concept sector, 10 stocks experienced an increase, with Rundu Co., Ltd. hitting the daily limit, and notable gains from Fosun Pharma, China Resources Sanjiu, and Haizheng Pharmaceutical, which rose by 3.94%, 3.10%, and 2.71% respectively [1][2] - The sector attracted a net inflow of 369 million yuan from main funds, with seven stocks receiving net inflows, and five stocks seeing inflows exceeding 30 million yuan [2] Group 2 - The leading stock in terms of net inflow was Rundu Co., Ltd., which saw a net inflow of 145 million yuan, followed by Fosun Pharma, Haizheng Pharmaceutical, and Zhejiang Medicine with net inflows of 101 million yuan, 53.91 million yuan, and 50.35 million yuan respectively [2][3] - In terms of fund inflow ratios, Rundu Co., Ltd., Zhejiang Medicine, and China Resources Sanjiu had the highest ratios, with net inflow rates of 42.20%, 11.87%, and 8.44% respectively [3] - The trading performance of the top stocks in the Artemisinin concept sector showed significant turnover rates, with Rundu Co., Ltd. at 10.26%, Fosun Pharma at 2.30%, and Haizheng Pharmaceutical at 5.63% [3]

Group 1 - Lin Yanglin, the chairman of Xinlicheng, has been placed under detention and is under investigation, which may impact investor confidence despite the company stating the matter is unrelated to its operations [1] - Weiming Pharmaceutical's stock will be suspended for one day due to its trial progress not meeting expectations and its subsidiary's inability to resume normal operations within three months, affecting performance expectations [2] - Tengsheng Bo Pharmaceutical has signed a licensing agreement with Health Yuan Group for the exclusive rights to research, develop, and commercialize BRII-693 in China, providing cash flow and enhancing market expectations [3] Group 2 - China Resources Double Crane announced a cash dividend of 3.71 yuan per 10 shares despite a decline in revenue and net profit, indicating strong cash flow and commitment to shareholders [4] - InnoTech's subsidiary has obtained long-term product certification for a flu detection kit, which is expected to enhance market competitiveness and potentially increase revenue [5]

Core Points - The company announced a cash dividend of 0.371 CNY per share for A shares, approved at the 2024 annual shareholders' meeting on May 16, 2025 [1] - The record date for the dividend is July 10, 2025, with the ex-dividend date and payment date both set for July 11, 2025 [1] Dividend Distribution Details - The total number of shares for the dividend distribution is based on the company's total share capital of 1,038,836,522 shares [1] - The cash dividend will be distributed to shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, after the market closes on the record date [1] - Shareholders who have not completed designated trading will have their dividends held by the clearing company until they complete the necessary procedures [1] Taxation Information - For individual shareholders holding shares for over one year, the dividend income is temporarily exempt from personal income tax, resulting in a net cash dividend of 0.371 CNY per share [2][3] - For shares held for one year or less, the company will not withhold personal income tax at the time of distribution; tax will be calculated upon the transfer of shares [2] - Qualified Foreign Institutional Investors (QFII) will have a 10% corporate income tax withheld, resulting in a net cash dividend of 0.3339 CNY per share [4] - Hong Kong investors through the Stock Connect will also have a 10% tax withheld, leading to the same net cash dividend of 0.3339 CNY per share [4] - Other institutional investors will receive the gross dividend of 0.371 CNY per share without tax withholding [5]